Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 7:02 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–15 of 15 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Intravenous linezolid Clear all

Conditions: Bacterial Infection
Interventions: ceftaroline, linezolid, Aztreonam; Drug
Lead sponsor: Forest Laboratories; Industry
Eligibility: 18 Years and older
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008
U.S. locations: 13
States / cities: Buena Park, California • Long Beach, California • Los Angeles, California + 10 more

Conditions: Community Acquired Bacterial Pneumonia
Interventions: Delafloxacin, Moxifloxacin, Linezolid; Drug
Lead sponsor: Melinta Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 860 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 25
States / cities: Montgomery, Alabama • Newark, Delaware • Coral Gables, Florida + 21 more

Conditions: Endocarditis
Interventions: Amoxycillin, Cefalexin, Dicloxacillin, Linezolid, Levofloxacin, Rifampicin, Ampicillin, Oxacillin, Vancomycin, Daptomycin, Ceftriaxone, Cefepime, Ceftaroline; Drug
Lead sponsor: West Virginia University; Other
Eligibility: 18 Years and older
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 1
States / cities: Morgantown, West Virginia

Conditions: Skin Diseases, Bacterial
Interventions: Intravenous iclaprim, Intravenous linezolid; Drug
Lead sponsor: Arpida AG; Industry
Eligibility: 18 Years to 90 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2006
U.S. locations: 2
States / cities: Naperville, Illinois • Casper, Wyoming

Conditions: Bacterial Infections
Interventions: Debio 1450 IV, Debio 1450 Oral, Linezolid, Debio 1450 Oral Placebo, Linezolid Placebo, Vancomycin IV; Drug
Lead sponsor: Debiopharm International SA; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 330 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 22
States / cities: Anaheim, California • Buena Park, California • Chula Vista, California + 17 more

Conditions: Complicated Skin and Skin Structure Infection
Interventions: intravenous iclaprim or intravenous linezolid; Drug
Lead sponsor: Arpida AG; Industry
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2006
U.S. locations: 5
States / cities: National City, California • Boise, Idaho • Indianapolis, Indiana + 2 more

Conditions: Skin and Subcutaneous Tissue Bacterial Infections
Interventions: Delafloxacin, Linezolid, Vancomycin; Drug
Lead sponsor: Melinta Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 256 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011
U.S. locations: 31
States / cities: Mobile, Alabama • Montgomery, Alabama • Buena Park, California + 27 more

Conditions: Endovascular Infection, Bone and Joint Infection, Skin and Soft Tissue Infection, Pulmonary Infection, Gastrointestinal Infection, Genitourinary Infection
Interventions: Amoxicillin, amoxicillin-clavulanate, cefadroxil, cefpodoxime, cefalexin, ciprofloxacin, delafloxacin, doxycycline, levofloxacin, linezolid, Ampicillin, ampicillin-sulbactam, cefazolin, cefepime, ceftaroline, ceftazidime, ceftazidime-avibactam, dalbavancin, daptomycin, ertapenem; Drug
Lead sponsor: West Virginia University; Other
Eligibility: 18 Years and older
Enrollment: 94 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 1
States / cities: Morgantown, West Virginia

Conditions: Neoplasms, Febrile Neutropenia
Interventions: CAZ-AVI, Vancomycin, Linezolid, Cefepime, Meropenem, Piperacillin/tazobactam; Drug
Lead sponsor: Forest Laboratories; Industry
Eligibility: 18 Years and older
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Febrile Neutropenia
Interventions: linezolid, vancomycin; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 13 Years and older
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2002
U.S. locations: 16
States / cities: Los Angeles, California • Springfield, Illinois • The Bronx, New York + 5 more

Conditions: Bacterial Infections
Interventions: Tedizolid (BAY119-2631), Placebo Tedizolid (BAY119-2631), Linezolid, Placebo Linezolid; Drug
Lead sponsor: Bayer; Industry
Eligibility: 18 Years and older
Enrollment: 598 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 5
States / cities: Chula Vista, California • La Mesa, California • Oceanside, California + 2 more

Conditions: Osteomyelitis
Interventions: oral antibiotics, intravenous antibiotics; Drug · Procedure
Lead sponsor: Julio Ramirez; Other
Eligibility: 18 Years to 100 Years
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2018
U.S. locations: 1
States / cities: Louisville, Kentucky

Conditions: Community Acquired Pneumonia
Interventions: lefamulin, Moxifloxacin, Linezolid; Drug
Lead sponsor: Nabriva Therapeutics AG; Industry
Eligibility: 18 Years and older
Enrollment: 551 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 7
States / cities: Hazard, Kentucky • Shreveport, Louisiana • Minneapolis, Minnesota + 4 more

Conditions: Methicillin Resistant Staphylococcus Aureus (MRSA)
Interventions: linezolid (Zyvox), vancomycin; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 1,225 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2010
U.S. locations: 108
States / cities: Birmingham, Alabama • Huntsville, Alabama • Montgomery, Alabama + 71 more

Conditions: Osteomyelitis
Interventions: Intravenous Antibacterial Agent, Oral Antibacterial Agent; Drug
Lead sponsor: Loyola University; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2017
U.S. locations: 1
States / cities: Maywood, Illinois

Search by objective public record fields.

Efficacy and Safety of Ceftaroline Versus Linezolid in Subjects With Complicated Skin and Skin Structure Infections

Study to Compare Delafloxacin to Moxifloxacin for the Treatment of Adults With Community-acquired Bacterial Pneumonia

Postoperative Antibiotic Management Duration Following Surgery for Intravenous Drug Abuse (IVDA) Endocarditis (OPTIMAL)

Study of Intravenous (I.V.) Iclaprim Versus Linezolid in Complicated Skin and Skin Structure Infections [cSSSI] (ASSIST-2)

Study of Debio 1450 for Bacterial Skin Infections

Phase 3 Safety and Efficacy Study of I.V. Iclaprim v Linezolid in cSSSI (ASSIST-1)

A Study to Assess Objective Endpoint Measurements of Response in Bacterial Skin Infections

Comparing Oral Versus Parenteral Antimicrobial Therapy

Comparative Study of Ceftazidime-Avibactam Versus Standard of Care as Therapy in Febrile Neutropenic Adults With Cancer

Treatment of Neutropenic Patients With Fever Who Are Suspected to Have A Gram Positive Infection

Efficacy and Safety of Intravenous to Oral 6-Day Tedizolid Phosphate vs. Intravenous to Oral 10-Day Linezolid in Patients With Acute Bacterial Skin and Skin Structure Infection (ABSSSI)

Patients Response to Early Switch To Oral:Osteomyelitis Study

Study to Compare Lefamulin to Moxifloxacin (With or Without Linezolid) for the Treatment of Adults With Pneumonia

Nosocomial Pneumonia With Suspected Or Proven Methicillin-Resistant Staphylococcus Aureus (MRSA)

Efficacy of Oral Antibiotic Therapy Compared to Intravenous Antibiotic Therapy for Osteomyelitis